ESG News For Gilead Sciences, Inc.

Event Set to Raise More Than $1 Million to Fund Breakthrough Breast Cancer Research as Diagnoses Rise Among Young Women

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their immune systems failed.

Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn’t know her parents suffered HIV-related complications, nor did she realize she’d been living with HIV since birth.

Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, has been awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award for her work in prevention.

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV.

We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations Society of America (PRSA).

We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco’s Golden Gate Park.

When Emma was diagnosed with triple-negative breast cancer, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back.

GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.

Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.

“Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.

At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the planet we all share.

Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.

At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical Development

Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data

This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.

As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools.

At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.

In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B (HBV) and with advanced HIV.

Annual Event to Fuel Research Advancements and Strengthen the Minnesota Community with Vital Support

Implementing culturally appropriate and innovative programs which meet patients at their point of need is sure to improve relinkage to care.

We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.

In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited.

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV epidemic are helping people living with lung cancer and their loved ones.

We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.

In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.

Take a spin through the latest in Gilead’s science and innovation in our new series, The Centrifuge Sessions.

Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE program with Gilead’s person-centric approach in mind to reach underserved communities and groups around the world.

The Children’s Inn at the National Institutes of Health (NIH) today announced that Gilead Sciences Inc. has awarded The Inn a $1 million grant to support its renovation and expansion. The grant will fund a welcome center in the new wing of The Inn of Tomorrow, a $50-plus million project for which The Inn recently held a groundbreaking ceremony. As the first point of contact, The Gilead Sciences Welcome Center is designed to ensure young patients from around the world participating in groundbreak

Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.

Improving health outcomes and reducing barriers to care starts in our own backyard. That’s why the Gilead Foundation’s HEAL Initiative is dedicating $5 million to helping build a Bay Area healthcare workforce that’s more diverse and representative of the patient population

We're prioritizing health equity for patients across the cancer care continuum. Our Gilead Oncology Grant supports 22 U.S. organizations with $3.15 million to provide resources for people affected by breast cancer.

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.

As a young gay professional, Terrell Parker spent several years working at the National Minority AIDS Council in Washington, D.C. during his 20s, advocating to help end the HIV epidemic and reduce stigma.

Together for a Cure: Fundraising Event Aims to Unite the Community for Breast Cancer Research and Support

Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the direction of renowned immunologist James Allison.

Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.

This year, we’re among 42 organizations being recognized by Seramount as a Leading Inclusion Index Company.

Maria underwent many more medical tests until a fibroscan conducted in 2018 by a hepatologist revealed that she had a rare autoimmune liver disease called primary biliary cholangitis, or PBC.

Transformative medicines have the greatest impact when they reach the people who need them most.

Cancer can cause disruption for families and may especially impact children.

For the third year in a row, Forbes has recognized Gilead as one of America’s Best Employers For Women.

Dr. Summer Sitima is one of 24 siblings born to a Kenyan family in the 90s at the height of the HIV epidemic in Sub Saharan Africa. She vividly remembers the day in 1997 that she first learned one of her older sisters was living with HIV.

Gilead Sciences, Inc. and the Elton John AIDS Foundation announced a five-year extension of the RADIAN ® partnership to help meet the needs of the most vulnerable key populations in Eastern Europe and Central Asia (EECA) where the HIV epidemic is growing.

As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals.

Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team.

Gilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally.

Luciana is a physician with more than 20 years of experience in pharma and she came to Gilead to help transform treatments for people living with cancer.

Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40.

In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a series of actions that organizations are taking to improve access and use of cancer screenings.